Table 3 Amikacin versus kanamycin use in MDR-TB treatment and the presence or absence of hearing loss
Aminoglycoside exposure | Any hearing loss | No hearing loss | Total |
|---|---|---|---|
Kanamycin | 168 (56Â %) | 134 (44Â %) | 302 |
Amikacin | 38 (75Â %) | 13 (25Â %) | 51 |
Total | 206 | 147 | 353 |